Enrollment rates varied widely by study type and institution.
Treatment response, progression-free survival, and overall survival were all associated with patient-reported outcomes.
The unrepresented patient population had a significantly increased risk of death at 5 years.
Several factors were associated with 30-day mortality.
The 3-year prostate cancer-specific survival decreased significantly for insured patients.
A retrospective review identified the underlying cause for cancer patients’ emergency department visits.
Investigators sought to determine if same-day administration of prophylactic pegfilgrastim was as effective as next-day administration.
Systematic screening of patients’ electronic health record helped identify those patients at risk of financial toxicity.
There was a significant increase in out-of-pocket costs for all 4 cancer types studied.